36 results about "Transdermal medication" patented technology

The invention discloses an intelligent drug delivery pain management bracelet, and relates to the fields of wearable equipment, transdermal drug delivery and biological signal processing. The bracelet is integrated with a multi-mode biosensor which comprises a temperature sensor, a pressure sensor, a heart rate sensor, a blood oxygen sensor and a skin electric response sensor, and physiological data related to pain can be collected in real time. Through an embedded microcontroller and a machine learning algorithm, a pain intensity evaluation model is constructed, and real-time evaluation of the pain state of a patient is realized. Based on the pain intensity and the physiological state of a patient, a drug release strategy is dynamically adjusted through an intelligent algorithm, and drugs are released painlessly and accurately through a micro-needle transdermal drug delivery technology, so that the patient obtains the optimal treatment effect. And the functions of data storage, historical analysis and remote doctor monitoring can be expanded. The hand ring is convenient to operate, comfortable to use and suitable for various pain management scenes such as chronic pain and postoperative pain, and the personalized level of pain treatment and patient compliance are remarkably improved.

A transdermal drug delivery device includes a reservoir, a transdermal membrane, a piston, a control rod, a spring, and a rotational cam. The reservoir is configured to hold a formulation. The transdermal membrane is configured to allow the formulation from the reservoir to pass therethrough. The piston is configured to move into the reservoir. The control rod is attached to the piston and includes a plurality of teeth thereon. The spring is configured to apply force to the control rod in the direction of the reservoir. The rotational cam has a first camming surface and a second camming surface that are configured to engage with the plurality of teeth. The rotational cam, when rotated, is configured to disengage the first camming surface from a first tooth of the plurality of teeth, thereby allowing the spring to advance the piston into the reservoir to expel the formulation onto the transdermal membrane.

To provide a weak current generating human application component capable of conveniently and efficiently transmitting a transdermal drug to a user's skin.SOLUTION: After a user pours an appropriate amount of water on a fiber layer 10 and allows water to permeate, when a thermoplastic resin soft film 40 is stuck to a skin 70, the fiber layer 10 containing a transdermal drug is directly used for the skin 70. Subsequently, the water supplied to the fiber layer 10 flows between a positive electrode 20 and a negative electrode 30 via multiple holes 21 formed in the positive electrode 20 and a polymer membrane 50, and when the water acting as an electrolyte in this way permeates between the positive electrode 20 and the negative electrode 30, a weak current is generated by a potential difference formed when reduction-oxidation reactions occur in the two electrodes 20 and 30 respectively. The generated weak current ionizes the transdermal drug, and then transmits the ionized transdermal drug to the inside of the skin 70 of the user.SELECTED DRAWING: Figure 1

Textile-integrated microsystem for transdermal drug delivery, characterized in that it has microstructured channels or micropores that enable non-invasive penetration of the upper skin layer.

The present application provides a low-temperature plasma patch for enhancing transdermal delivery of useful substances and a transdermal delivery method using same. More specifically, the present application provides a low-temperature plasma patch for enhancing transdermal delivery of useful substances and a transdermal delivery method using same, wherein the patch can be attached to the skin to temporarily weaken the skin barrier and facilitate the delivery of useful substances such as transdermal drugs.

A pharmaceutical composition, and methods for using a pharmaceutical composition, for treating osteoarthritis in a subject in need thereof, the pharmaceutical composition including cannabidiol or a pharmaceutically acceptable salt thereof; and especially wherein administration of the cannabidiol is by a transdermal pharmaceutical gel composition. A method is disclosed for treating one or more symptoms of osteoarthritis in a patient. The method includes transdermally administering an effective amount of cannabidiol (CBD) to the patient wherein one or more symptoms of osteoarthritis are treated in the patient.

The invention provides a microsphere composition for a contraceptive microneedle and the contraceptive microneedle containing the composition. The microsphere composition for the contraceptive microneedle comprises one selected from the group consisting of sustained-release estrogen microspheres, sustained-release progesterone microspheres and mixtures thereof, and the sustained-release estrogen microspheres comprise 400-600 parts by weight of biodegradable polymer per 100 parts by weight of estrogen, every 100 parts by weight of progesterone and hydroxypropyl-beta-cyclodextrin (HP [beta] CD) in the sustained-release progesterone microspheres comprise 700-900 parts by weight of a biodegradable polymer, and the molar ratio of the progesterone to the hydroxypropyl-beta-cyclodextrin is (1: 2)-(1: 3). The microsphere composition for a contraceptive microneedle according to the present invention can stably encapsulate a drug, exhibits a sustained-release drug effect for at least one week, and has a particle size (Dv90) suitable for a microneedle. According to the contraceptive microneedle or the contraceptive microneedle patch, administration is convenient, the contraceptive microneedle or the contraceptive microneedle patch is used once a week, the transdermal medicine permeability is good, the short attachment time is allowed, and the medicine is slowly released for at least one week.

The present disclosure provides transdermal drug delivery systems, methods, and platforms. In one example, the smart patch includes a drug-containing layer, a communication interface, and one or more sensors configured to detect a status change of the smart patch to the smart patch, the status change of the smart patch including one or more of removing a packaging from the smart patch and applying the smart patch to skin of the patient. The smart patch further includes a processor communicatively coupled to the one or more sensors and the communication interface, wherein the processor is configured to perform operations including automatically transiting between a plurality of working conditions based on the status change of the smart patch, the plurality of working conditions of the smart patch comprising a hibernation mode, a sleep mode, and a work mode and transmitting smart patch usage data via the communication interface.

Disclosed are a microneedle patch including a first hydrogel layer containing a mussel adhesive protein and hyaluronic acid, and a second hydrogel layer containing silk fibroin, and a preparation method thereof. The microneedle patch according to the present disclosure has excellent tissue adhesion, biocompatibility, and biodegradability, and is used for transdermal drug delivery to promote wound regeneration.

The invention belongs to the technical field of biology, and discloses application of a composition of neoagaro-oligosaccharide and astaxanthin in preparation of a transdermal drug for treating osteoarthritis and a composite gel preparation. The composition provided by the invention comprises neoagaro-oligosaccharide, astaxanthin, carbomer and alginate in a mass ratio of (1-10): (1-10): (0.01-0.5): (0.1-1), and can realize efficient enrichment of neoagaro-oligosaccharide and astaxanthin in an articular cavity through a substance diffusion path of skin penetration, deep tissue diffusion, joint capsule permeation and articular cavity enrichment, so that the content of neoagaro-oligosaccharide and astaxanthin in the articular cavity is improved, and the content of astaxanthin in the articular cavity is reduced. The new agar oligosaccharide and the astaxanthin have an excellent synergistic effect, so that the acute inflammation symptom of gouty osteoarthritis can be efficiently relieved, the progress of the disease course is blocked, the pathological change of joint tissue is repaired, and the new agar oligosaccharide and the astaxanthin have an excellent application prospect in preparation of the transdermal medicine for treating osteoarthritis.

The application belongs to the technical field of biotechnology, and discloses application of a new sialyloligosaccharide and astaxanthin composition in preparation of a transdermal drug for treating osteoarthritis and a composite gel preparation. The composition provided by the application comprises new sialyloligosaccharide, astaxanthin, carbomer and alginate with a mass ratio of (1-10):(1-10):(0.01-0.5):(0.1-1). The composition can realize efficient enrichment of the new sialyloligosaccharide and astaxanthin in the joint cavity through a diffusion pathway of skin penetration, deep tissue diffusion, joint capsule penetration and joint cavity enrichment of the substance, and the new sialyloligosaccharide and astaxanthin have excellent synergistic effects, can efficiently relieve acute inflammatory symptoms of gouty osteoarthritis, block the disease progression and repair the joint tissue pathological changes, and have excellent application prospects in preparation of the transdermal drug for treating osteoarthritis.

Transdermal drug delivery systems and methods of fabricating such systems are provided. The active pharmaceutical ingredient (API) can have a water solubility of less than about 10 milligrams per milliliter, a melting point greater than about 120° C., and a log P value ranging from about −2 to about 8. More particularly, the present disclosure is directed to improving the permeation of such compounds through the skin by forming a molecular solid suspension of the drug (API) on a carrier suspended within a drug-in-adhesive layer.

The present disclosure provides transdermal drug delivery systems, methods, and platforms. In one example, the smart patch includes a drug-containing layer, a communication interface, and one or more sensors configured to detect a status change of the smart patch to the smart patch, the status change of the smart patch including one or more of removing a packaging from the smart patch and applying the smart patch to skin of the patient. The smart patch further includes a processor communicatively coupled to the one or more sensors and the communication interface, wherein the processor is configured to perform operations including automatically transiting between a plurality of working conditions based on the status change of the smart patch, the plurality of working conditions of the smart patch comprising a hibernation mode, a sleep mode, and a work mode and transmitting smart patch usage data via the communication interface.

A microneedle particle arranged to be rolled and massaged on a subject's skin to penetrate the stratum corneum is disclosed. The microparticle comprises a support body, and a plurality of microneedles protruding from the support body (20), each microneedle comprising a tip. The support body maintains the microneedles and tips in a predetermined conformation allowing the microneedle particle to be rolled on the skin. The microneedles have an average tip sharpness radius of less than 20 μm, an average microneedle length of less than 100 μm, and an average tip sharpness to microneedle length ratio of 1:5 to 1:200. Formulations and kits for said use are provided. A microneedle particle manufacturing method using a non-linear two-photon absorption process, a non-therapeutic cosmetic method of skin treatment, and a method of drug delivery through the skin for said microneedle particle are disclosed.

A transdermal drug administration system comprising: a first ultrasonic wave production means that emits first ultrasonic waves with a low frequency into skin, in order to cause peeling due to cavitation in the stratum corneum of the skin; and a second ultrasonic wave production means that produces an acoustic flow by emitting second ultrasonic waves with a higher frequency than that of the first ultrasonic waves, in order to cause a drug to penetrate under the corneum in which the peeling has occurred.

The present invention relates to a casing, a lower housing of said casing defining a skin contact surface with an orifice for the passage of a transdermal injection cannula, a reservoir containing an active ingredient for administration, a pump system comprising a pump body, a valve piston and a pump piston, each of these two pistons being capable of axial movement within the pump body by a drive system, and a transdermal injection system and an electronic control system for operating the drive systems of the pump system and for releasing the transdermal injection system for the transdermal insertion of said cannula. Abstract figure: Figure 1

Described herein are compositions (e.g., topical formulations) including andrographolides (ANGL), epigallocatechin gallate (EGCG), or a combination thereof, and methods of making and using the same.

A portable brace assembly for therapeutically supporting an area of a user's body. The assembly generally includes a belt configured to be positioned around the user. One or more inflatable bladders are attached to the belt. One or more additional therapeutic or support modalities configured to be combined with the belt. The additional modalities may be positioned over the inflatable bladders, so that in use the additional modalities are positioned between the inflatable bladders and the user's body. A transdermal medication delivery assembly may be configured to be combined with the first side of the belt as an additional modality.

The present invention relates to the development of antibacterial biocellulosic patches / membranes for transdermal drug delivery. Novel high cellulose producing bacterial strain Komagataeibacter hansenii (MBS-8) has been isolated. The production and purification process of biocellulosic membranes is developed in such a way that the membranes produced are of desired thickness and length, suitable for drug impregnation in a cost-effective manner for the development of transdermal patches. Further, a process for efficient drug impregnation of Mupirocin in BC membranes has been developed. Weight and drug content of mupirocin impregnated BCM were found to be uniform.

The present disclosure provides transdermal drug delivery systems, methods, and platforms. In one example, a smart patch includes a drug-containing layer, a communication interface, and one or more sensors configured to detect a state change between the smart patches, the state change of the smart patch including one or more of removing a package from the smart patch and applying the smart patch to the skin of a patient. The smart patch further includes a processor communicatively coupled with the one or more sensors and the communication interface, where the processor is configured to perform operations including automatically transitioning between a plurality of operating conditions based on a change in state of the smart patch and transmitting smart patch usage data through the communication interface, the plurality of working conditions of the intelligent patch comprise a sleep mode, a sleep mode and a working mode.

Provided herein are devices and methods for transdermal delivery of drugs into the systemic circulation, including a drug-loaded microneedle patch and a force-calibrated tractive counterpart. The tractive counterpart provides a force that is calibrated to hold the microneedles in the skin but not to impair capillary perfusion. Embodiments are described that comprise two microneedle patches, e.g., wherein the microneedles of one such patch are staggered with reference to the other patch, and wherein the weight of the patches is controlled to allow the device to remain in place despite movement of the subject who wears it.

The invention discloses a ropinirole transdermal pharmaceutical composition as well as a preparation method and application thereof, and belongs to the technical field of veterinary drugs. The composition comprises, by weight, 1%-30% of ropinirole or pharmaceutically acceptable salt of ropinirole as an active component, and at least one transdermal promoting solvent, and can be prepared into a transdermal non-aqueous solution, a transdermal ointment, a transdermal gel preparation or a transdermal patch and other dosage forms.

The invention belongs to the technical field of transdermal medicinal preparations, and particularly relates to a matrine hydrogel transdermal patch as well as a preparation method and application thereof. The transdermal patch comprises a back lining layer, a medicine storage layer and a protective layer which are sequentially stacked, and the medicine storage layer is prepared from the following raw materials in parts by weight: 8-15 parts of sophocarpidine, 8-15 parts of a gel matrix, 3-6 parts of ethanol, 0.3-1.5 parts of a penetration enhancer, 3-10 parts of a humectant and the balance of a pH buffer solution, totaling 100 parts. The matrine transdermal patch is high in drug loading capacity, excellent in transdermal efficiency, lasting in slow release performance, good in biocompatibility, high in stability and comfortable to apply, and can be used for long-acting treatment of chronic hepatitis, non-alcoholic fatty liver diseases and tumor diseases.

Provided is a transdermal drug delivery system comprising tetrahydrocannabinol (THC). Transdermal delivery can provide a drug plasma concentration at predetermined rate for a predetermined period of time with a simplified therapeutic regimen by decreasing dosing frequency for the treatment and / or prevention of pain and / or inflammation.

A transdermal drug delivery patch is provided that can be adapted for immediate release applications of agents having a relatively low molecular weight. The transdermal drug delivery patch is provided with a matrix and at least one drug disposed within the matrix, wherein the matrix has a water retention capacity of 10 mg / cm<supgt;2< / supgt; or less, and the drug is an agent having a molecular weight of 5000 or less.

The present invention significantly improves transdermal drug skin permeability from a matrix-type transdermal absorption preparation by utilizing dermal pores punctured by using microneedles.　In a microneedle transdermal preparation of the present invention: a microneedle array comprises a substrate and microneedles erected on the substrate; a bottom surface drug-containing layer is provided above the substrate when the tips of the microneedles are directed upward; and the bottom surface drug-containing layer has recesses between the microneedles.

This disclosure provides methods and devices for providing nutrients (e.g., oxygen, vitamins, or minerals) or a transdermal drug into a body of a subject through the subject' s skin.

The present disclosure provides transdermal drug delivery systems, methods, and platforms. In one example, the smart patch includes a drug-containing layer, a communication interface, and one or more sensors configured to detect a status change of the smart patch to the smart patch, the status change of the smart patch including one or more of removing a packaging from the smart patch and applying the smart patch to skin of the patient. The smart patch further includes a processor communicatively coupled to the one or more sensors and the communication interface, wherein the processor is configured to perform operations including automatically transiting between a plurality of working conditions based on the status change of the smart patch, the plurality of working conditions of the smart patch comprising a hibernation mode, a sleep mode, and a work mode and transmitting smart patch usage data via the communication interface.

Disclosed herein are acoustofluidic transdermal drug delivery devices, systems, and methods for delivering a therapeutic agent to a subject or sampling a biofluid, such as interstitial fluid or blood, from the body of the subject. The disclosed device, systems, and methods involve application of an AC signal, such as radiofrequency, which generates surface acoustic waves (SAWs) upon interacting with the device, thereby inducing a streaming flow capable of enabling transdermal drug delivery or transdermal sampling of a biofluid.